FAQ Library

FAQ Library published on April 11, 2022
Join Dr. Usmani as he describes how clinicians should monitor patients after their first or second dose after switching from IV daratumumab to subcutaneous.
FAQ Library published on April 6, 2022
Dr. Lonial discusses the impact of safety and efficacy in four-drug regimens compared to the three-drug regimens for frontline therapy.
FAQ Library published on March 25, 2021
In this activity, Dr. Baljevic discusses the side-effect profile associated with four-drug regimens.
FAQ Library published on March 23, 2021
In this activity, Dr. Baljevic explains the NCCN guidelines outlining four-drug combinations listed for use in newly diagnosed transplant-eligible patients.
FAQ Library published on January 20, 2021
In this activity, Dr. Raje provides a summary of the KarMMa trial and BB2121 in relapsed/refractory multiple myeloma.
FAQ Library published on January 14, 2021
Dr. Raje explains therapeutic interventions for smoldering multiple myeloma, as well as how to better risk-stratify patients.
FAQ Library published on January 12, 2021
In this activity, Dr. Noopur Raje discusses how to risk-stratify patients with smoldering myeloma and the updated definition of symptomatic myeloma.
FAQ Library published on November 18, 2020
In this activity, Dr. Usmani describes RVD lite and where to utilize this regimen best in practice.

Results 1 - 8 of 8